Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 8/20 | 0.85 |
| ▸ | HTR2C | P28335 | 9/20 | 0.71 |
| ▸ | HTR2B | P41595 | 4/20 | 0.71 |
| ▸ | DRD2 | P14416 | 6/20 | 0.62 |
| ▸ | DRD3 | P35462 | 6/20 | 0.62 |
| ▸ | HTR2A | P28223 | 6/20 | 0.62 |
| ▸ | MLNR | O43193 | 3/20 | 0.62 |
| ▸ | GHSR | Q92847 | 1/20 | 0.58 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.57 |
| ▸ | KCNAB1 | Q14722 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5781306 | 0.92 | HTR6 (1.00) | HTR6HTR2CHTR2BDRD2DRD3 | |
| SCHEMBL6364800 | 0.88 | HTR2C (0.72) | HTR6HTR2CHTR2BDRD2DRD3 | |
| SCHEMBL3353772 | 0.85 | HTR6 (0.62) | HTR6HTR2CHTR2BDRD2DRD3 | |
| Hydrochloric Acid SCHEMBL6365049 | 0.84 | HTR6 (0.64) | HTR6HTR2CHTR2BDRD2DRD3 | |
| SCHEMBL10357482 | 0.84 | HTR6 (0.84) | HTR6HTR2CHTR2BDRD2DRD3 | |
| SCHEMBL7452220 | 0.84 | HTR6 (0.84) | HTR6HTR2CHTR2BDRD2DRD3 | |
| SCHEMBL1946627 | 0.84 | LMNA (0.77) | HTR6HTR2CHTR2BDRD2DRD3 | |
| Hydrochloric Acid SCHEMBL10563577 | 0.83 | HTR6 (0.82) | HTR6HTR2CHTR2BDRD2DRD3 | |
| SCHEMBL6365855 | 0.81 | PNMT (0.80) | HTR6HTR2CHTR2BDRD2DRD3 | |
| SCHEMBL1960175 | 0.81 | HTR6 (0.70) | HTR6HTR2CHTR2BDRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110130383-A1 | Use of Ion Channel Modulators in the Prophylaxis and Treatment of Inflammatory and Immunological Diseases | LECTUS THERAPEUTICS LIMITED (GB) | 2011-06-02 | — | — | US | disclosed |
| US-20110130383-A1 | Use of Ion Channel Modulators in the Prophylaxis and Treatment of Inflammatory and Immunological Diseases | LECTUS THERAPEUTICS LIMITED (GB) | 2011-06-02 | — | — | US | disclosed |
| US-20090318423-A1 | Ion Channel Modulators & Uses Thereof | LECTUS THERAPEUTICS LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
| US-20090318423-A1 | Ion Channel Modulators & Uses Thereof | LECTUS THERAPEUTICS LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
| US-20090318423-A1 | Ion Channel Modulators & Uses Thereof | LECTUS THERAPEUTICS LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
| EP-2069309-A1 | ION CHANNEL MODULATORS&USES THEREOF | Lectus Therapeutics Limited (GB) | 2009-06-17 | — | — | EP | disclosed |
| EP-2066317-A2 | USE OF ION CHANNEL MODULATORS IN THE PROPHYLAXIS AND TREATMENT OF INFLAMMATORY AND IMMUNOLOGICAL DISEASES | Lectus Therapeutics Limited (GB) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008038051-A2 | USE OF ION CHANNEL MODULATORS IN THE PROPHYLAXIS AND TREATMENT OF INFLAMMATORY AND IMMUNOLOGICAL DISEASES | LECTUS THERAPEUTICS LIMITED (GB) | 2008-04-03 | — | — | WO | disclosed |
| WO-2008038053-A1 | ION CHANNEL MODULATORS & USES THEREOF | LECTUS THERAPEUTICS LIMITED (GB) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318423-A1 | Ion Channel Modulators & Uses Thereof | KCNH3, KCNN3, KCNH2 | HTR6 582/4885HTR2C 433/4885HTR2B 574/4885 |
| US-20110130383-A1 | Use of Ion Channel Modulators in the Prophylaxis and Treatment of Inflammatory and Immunological Diseases | HCAR2, HCAR1, SCN7A | HTR6 696/4885HTR2C 621/4885HTR2B 655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.